Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives $5.50 Consensus PT from Analysts

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) has been given an average recommendation of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and four have assigned a strong buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $5.50.

Several research analysts have recently weighed in on IKT shares. LADENBURG THALM/SH SH started coverage on Inhibikase Therapeutics in a report on Wednesday, March 4th. They set a “buy” rating and a $4.00 target price on the stock. Lifesci Capital upgraded Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, February 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Tuesday, April 21st.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Sands Capital Alternatives LLC boosted its holdings in shares of Inhibikase Therapeutics by 18.9% during the 4th quarter. Sands Capital Alternatives LLC now owns 13,018,965 shares of the company’s stock worth $26,689,000 after purchasing an additional 2,068,965 shares during the last quarter. ADAR1 Capital Management LLC lifted its holdings in Inhibikase Therapeutics by 53.7% in the fourth quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock valued at $16,531,000 after acquiring an additional 2,816,346 shares during the last quarter. Siren L.L.C. acquired a new position in Inhibikase Therapeutics in the fourth quarter valued at approximately $11,992,000. Commodore Capital LP lifted its holdings in Inhibikase Therapeutics by 1.0% in the second quarter. Commodore Capital LP now owns 5,397,488 shares of the company’s stock valued at $10,525,000 after acquiring an additional 53,056 shares during the last quarter. Finally, Squadron Capital Management LLC acquired a new position in Inhibikase Therapeutics in the fourth quarter valued at approximately $8,661,000. 3.81% of the stock is currently owned by institutional investors and hedge funds.

Inhibikase Therapeutics Trading Down 2.3%

IKT stock opened at $1.71 on Tuesday. Inhibikase Therapeutics has a 12-month low of $1.33 and a 12-month high of $2.26. The stock has a market cap of $225.77 million, a price-to-earnings ratio of -3.98 and a beta of 0.93. The business’s 50-day moving average is $1.78 and its 200 day moving average is $1.74.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). As a group, equities analysts forecast that Inhibikase Therapeutics will post -0.41 EPS for the current fiscal year.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.